The global shift towards preventative health and personalized medicine is fueling unprecedented growth in the sleep technology market, projected to reach ~$45B–$50B globally by 2027 (AI est.). Regulatory bodies are increasingly emphasizing data-driven health outcomes, while competitive pressures demand innovative, user-friendly solutions. This technology's non-invasive, high-accuracy approach aligns perfectly with these trends, offering a critical advantage for companies seeking to capture market share in digital therapeutics, remote patient monitoring, and consumer wellness.
Integrates respiratory rate variability and heart rate data to estimate NREM and REM sleep stages with higher accuracy than conventional methods.
Utilizes respiratory, heart rate, and body movement data obtainable from wearable devices, significantly reducing user burden and promoting daily use.
Overcame nine prior art rejections to achieve registration, indicating strong validity and a high competitive advantage.
This patent successfully overcame nine prior art rejections, demonstrating strong validity and robust defense against competitive challenges. The six claims comprehensively protect the technical features of NREM sleep determination using respiratory data variability and REM sleep determination combined with heart rate data, providing a solid foundation for licensees.
This patent primarily covers the algorithm for sleep stage determination from basic physiological data. White space exists in developing integrated hardware solutions, advanced predictive analytics for sleep disorder onset, or therapeutic interventions based on these insights, allowing for complementary IP development.
Estimates expert analysis labor for polysomnography (PSG) in medical and research institutions. Assuming 20,000 analyses per year at 1 hour/case and a labor cost of ~$33/hour (AI est.), this technology could reduce analysis effort by 25%, leading to an annual cost reduction of ~$150K (AI est.).
X: Sleep Stage Determination Accuracy
Y: User Convenience